Top

Current Pain and Headache Reports

Published in:

01-02-2022 | Coronavirus | Chronic Pain Medicine (O Viswanath, Section Editor)

A Review of Sublingual Sufentanil Tablet (SST) and its Utility as an Analgesic Agent for Pain Procedures

Authors: Sarang S. Koushik, Ruben H. Schwartz, Denis Cherkalin, Vignesh Sankar, Naum Shaparin, Omar Viswanath

Published in: Current Pain and Headache Reports | Issue 2/2022

Abstract

Purpose of Review

Sedation for pain medicine procedures provides a unique challenge for proceduralists. Many patients dealing with pain are on chronic opioids and require higher doses of sedation for adequate procedural comfort. Chronic pain patients have various comorbidities including depression, neuropsychiatric disorders, peripheral vascular disease, and renal impairment, among others [1]. These confounding variables make the overall treatment of their pain condition much more challenging.

Recent Findings

For patients requiring intravenous (IV) sedation for their pain procedures, the constant need for access may render them a “difficult stick” over time. Another factor to consider is the increasing requirements by the hospital system needing IV sedatives and analgesics in the intensive care unit and operating rooms during the coronavirus (COVID-19) pandemic.

Summary

Sublingual sufentanil (SST) provides an excellent analgesic option for patients undergoing interventional pain procedures. The use of SST allows hospitals to preserve IV agents for more critical areas and mitigates the difficulty of obtaining IV access in patients.

Dahan A, van Velzen M. Marieke Niesters; Comorbidities and the Complexities of Chronic Pain. Anesthesiology. 2014;121:675–7. https://doi.org/10.1097/ALN.0000000000000402.CrossRefPubMed

• Miner JR, Rafique Z, Minkowitz HS, DiDonato KP, Palmer PP. Sufentanil sublingual tablet 30mcg for moderate-to-severe acute pain in the ED. Successfully demonstrated sufentanil as a potent and useful analgesic agent in the emergency room, outside of the typical operating room setting. Am J Emerg Med. 2018;36(6):954–961. Epub 2017 Oct 31.

Fisher DM, Chang P, Wada DR, Dahan A, Palmer PP. Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. Anesthesiology. 2018;128(5):943–952.

Niemegeers CJ, Schellekens KH, Van Bever WF, Janssen PA. Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs. Arzneimittel-Forschung. 1976;26(8):1551–6. PMID 12772.

https://www.asahq.org/advocacy-and-asapac/fda-and-washington-alerts/washington-alerts/2020/03/asa-urges-congress-to-include-legislation-to-address-drug-shortages-in-covid-19-legislative-packages. Accessed 8 Oct 2021.

Manzi JE, Jones MR, Cornett EM, Kaye AD. Moderate and deep procedural sedation-the role of proper monitoring and safe techniques in clinical practice. Curr Opin Anaesthesiol. 2021;34(4):497–501. https://doi.org/10.1097/ACO.0000000000001011.CrossRefPubMed

Griffin CE, Kaye AM, Rivera Bueno F, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13:214–23.PubMedPubMedCentral

Richter JJ. Current theories about the mechanisms of benzodiazepines and neuroleptic drugs. Anesthesiology. 1981;54(1):66–72.CrossRef

Wehrmann T, Riphaus A. Sedation with propofol for interventional endoscopic procedures: a risk factor analysis. Scand J Gastroenterol. 2008;43:368–74. https://doi.org/10.1080/00365520701679181.CrossRefPubMed

10.

Tran T, Beutler S, Urman R. Moderate and deep sedation training and pharmacology for nonanesthesiologists. Curr Opin Anaesthesiol. 2019;32(4):457–63. https://doi.org/10.1097/ACO.0000000000000758.CrossRefPubMed

11.

Fisher DM, et al. Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. Anesthesiology. 2018;128(5):943–952. https://doi.org/10.1097/ALN.0000000000002145

12.

Minkowitz HS, et al. Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study. Pain Practice : Official J World Institute Pain 2017;17(7):848–858. https://doi.org/10.1111/papr.12531

13.

Miner JR, et al. Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. Pain Manag 2019;9(3):259–271. https://doi.org/10.2217/pmt-2018-0090

14.

Leiman D, et al. Patient and Healthcare Professional Satisfaction Ratings and Safety Profile of Sufentanil Sublingual Tablets for Treatment of Acute Pain: A Pooled Demographic Analysis. J Pain Res 2021;14:805–813. 25. https://doi.org/10.2147/JPR.S291359

15.

Hutchins JL, et al. An Open-Label Study of Sufentanil Sublingual Tablet 30 Mcg in Patients with Postoperative Pain. Pain medicine (Malden, Mass.) 2018;19(10):2058–2068. https://doi.org/10.1093/pm/pnx248

16.

Melson TI, et al. Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial. Pain Practice : Official J World Institute Pain 2014;14(8):679–88. https://doi.org/10.1111/papr.12238

17.

Katz P, et al. Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison. Current Med Res Opinion 2017;33(5):899–910. https://doi.org/10.1080/03007995.2017.1294559

18.

•• Hutchins JL, et al. Pooled Dosing and Efficacy Analysis of the Sufentanil Sublingual Tablet 30 mcg Across Demographic Subgroups for the Management of Moderate-to-Severe Acute Pain. J Perianesthesia Nursing : Official J Am Soc Perianesthesia Nurse. 2020;35(1): 22–28. https://doi.org/10.1016/j.jopan.2019.08.009. This study showed efficacy of sufentanil in reducing pain scores compared to placebo across numerous subgroups deeming the medication safe and reliable.

19.

Katz P, et al. Indirect treatment comparison of two non-invasive patient-controlled analgesia treatments for acute post-operative pain management. Curr Med Res Opinion. 2017;33(5):911–918. https://doi.org/10.1080/03007995.2017.1294560

20.

Meuser T, et al. Staff time requirements for postoperative pain management: Comparison of sufentanil sublingual tablet system and intravenous patient-controlled analgesia. J Opioid Manag. 2019;16,1 (2019):33–39. https://doi.org/10.5055/jom.2020.0548

21.

Pogatzki-Zahn E, et al. Real-world use of the sufentanil sublingual tablet system for patient-controlled management of acute postoperative pain: a prospective noninterventional study. Curr Med Res Opinion 2020;6(2):277–284. https://doi.org/10.1080/03007995.2019.1681133

22.

Meijer F, et al. Sublingual sufentanil for postoperative pain relief: first clinical experiences. J Pain Res. 2018;11:987–992. https://doi.org/10.2147/JPR.S160091

23.

Amson H, et al. Usability evaluation of sufentanil sublingual tablet analgesia in patients following Enhanced Recovery After Surgery. J Comp Eff Res. 2021;10(9):743–750. https://doi.org/10.2217/cer-2020-0239

24.

Noel E, et al. Sufentanil sublingual tablet system versus oral oxycodone for management of postoperative pain in enhanced recovery after surgery pathway for total knee arthroplasty: a randomized controlled study. J Exp. Orthop. 2020;7(1):92. https://doi.org/10.1186/s40634-020-00306-x

25.

Scardino M, et al. Sublingual sufentanil tablet system Zalviso® for postoperative analgesia after knee replacement in fast track surgery: a pilot observational study. J Exp Orthop. 2018;5(1):8. https://doi.org/10.1186/s40634-018-0123-y

26.

Van Tittelboom V, et al. Sublingual Sufentanil Tablet System Versus Continuous Morphine Infusion for Postoperative Analgesia in Cardiac Surgery Patients. J Cardiothorac Vasc Anesthesia. 2021;35(4):1125–1133. https://doi.org/10.1053/j.jvca.2020.08.030

27.

Lomangino I, et al. Sublingual sufentanil in pain management after pulmonary resection: a randomized prospective study. Ann Thoracic Surg. 2020;S0003–4975(21):01294–7. https://doi.org/10.1016/j.athoracsur.2021.06.063

28.

Fabio C, et al. Sufentanil sublingual tablet system (Zalviso®) as an effective analgesic option after thoracic surgery: An observational study. Saudi J Anaesthesia. 2019;13(3):222–226. https://doi.org/10.4103/sja.SJA_109_19

29.

Leykin Y, et al. Sublingual sufentanil tablet system for postoperative analgesia after gynecological surgery. Minerva Medica. 2019;110(3):209–215. https://doi.org/10.23736/S0026-4806.19.05992-5

30.

Koth MC, Shannon MH, James CS, Mark DC. A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain. 2020;8(5):6.

31.

Tvetenstrand CD, Wolff ME. Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting. J Clin Anesth Pain Manag. 2020;4(2):123–8.

32.

van de Donk T, et al. Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management. Anaesthesia. 2018;73(2):231–7. https://doi.org/10.1111/anae.14132.CrossRefPubMed

33.

Kim SY, Buckenmaier CC, Howe EG, Choi KH. The Newest Battlefield Opioid, Sublingual Sufentanil: A Proposal to Refine Opioid Usage in the U.S. Military. Military Med. 2021;usab395. https://doi.org/10.1093/milmed/usab395

34.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506.CrossRef

35.

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.CrossRef

36.

FDA Drug Shortages [online] . Accessed October 1, 2021. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm

37.

ASHP Drug Shortages [online]. Accessed October 1, 2021. https://www.ashp.org/Drug-Shortages.

38.

Agency DE. DEA takes additional steps to allow increased production of controlled substances used in COVID-19 care. https://www.dea.gov/press-releases/2020/04/07/dea-takes-additional-steps-allow-increased-production-controlled. Accessed October 1, 2021.

39.

Narayanan M, Venkataraju A, Jennings J. Analgesia in intensive care: part 1. BJA Education. 2015;16(2):72–8.CrossRef

Title: A Review of Sublingual Sufentanil Tablet (SST) and its Utility as an Analgesic Agent for Pain Procedures
Authors: Sarang S. Koushik
Ruben H. Schwartz
Denis Cherkalin
Vignesh Sankar
Naum Shaparin
Omar Viswanath
Publication date: 01-02-2022
Publisher: Springer US
Keywords: Coronavirus
Sufentanil
Opioids
Opioids
Analgesics in Dentistry
Morphine
COVID-19
Midazolam
Published in: Current Pain and Headache Reports / Issue 2/2022
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-022-01014-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A Review of Sublingual Sufentanil Tablet (SST) and its Utility as an Analgesic Agent for Pain Procedures

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2022

Correction to: Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data

Premonitory and Accompanying Symptoms in Childhood Migraine

Opioid Use Disorder and Racial/Ethnic Health Disparities: Prevention and Management

Enhanced Recovery After Surgery: Opioid Sparing Strategies After Discharge: A Review

Gabapentinoid Use in Perioperative Care and Current Controversies

Modulatory Effects of Stem Cells on Opioid Receptors and Neuroinflammation